AbbVie has inflammatory bowel disease covered with blockbuster drugs now on the market and additional drug candidates in clinical development. The pharmaceutical giant is diversifying its IBD ...

The inflammatory bowel disease therapy succeeded in its first major testing, setting up a competition with several large drugmakers.

Please provide your email address to receive an email when new articles are posted on . Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, presents a complex ...

Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. — and a new artificial intelligence-generated drug could help alleviate symptoms. Insilico Medicine, an AI-driven biotech ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said.

Some patients enrolled at Providence, R.I.-based University Gastroenterology have begun to see a clinical trial of ozaminod, 10 WJAR reported Oct. 8. The prospective phase 4, open-label study began in ...

Microbiota therapeutics, such as fecal microbiota transplantation (FMT), could offer more diverse, personalized treatment options for patients with inflammatory bowel disease (IBD), particularly for ...

In a recent study published in eBioMedicine, researchers performed a meta-analysis to explore the impact of mood interventions on inflammatory disease activity in inflammatory bowel disease (IBD).

Insurance data cast doubt on broad recommendations against their use ...